1443040-75-2

Upstream product

• 1443040-74-1 ethyl 2-((2S,4S,6S)-6-(((2R,4R,6R)-6-((R)-2-((tert-butyldimethylsilyl)oxy)heptadecyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)acetate 
• 1443040-66-1 ethyl 2-((2S,4S,6S)-6-(((2S,4S,6S)-6-((R)-2-hydroxyheptadecyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)acetate 
• 1443040-63-8 ethyl 2-((2S,4S,6S)-6-(((2S,4S,6S)-6-((S)-2-hydroxyheptadec-3-yn-1-yl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)acetate 
• 1443040-62-7 ethyl 2-((2S,4S,6S)-6-(((2R,4R,6R)-6-(2-oxoheptadec-3-yn-1-yl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)acetate 
• 1443040-61-6 ethyl 2-((2S,4S,6S)-6-(((2R,4R,6R)-6-(2-oxoethyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)acetate 
• 1443040-60-5 ethyl 2-((2S,4S,6S)-6-(((2S,4S,6S)-6-(2-hydroxyethyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)acetate 
• 1443040-53-6 2-((2S,4S,6S)-6-(2-((4-methoxybenzyl)oxy)ethyl)-2-phenyl-1,3-dioxan-4-yl)acetaldehyde 
• 1443040-59-2 ethyl 2-((2S,4S,6S)-6-(((2S,4S,6S)-6-(2-((4-methoxybenzyl)oxy)ethyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)acetate 
• 1443040-52-5 methyl 2-((2S,4S,6S)-6-(2-((4-methoxybenzyl)oxy)ethyl)-2-phenyl-1,3-dioxan-4-yl)acetate 
• 1443040-54-7 (R)-1-((2S,4R,6S)-6-(2-((4-methoxybenzyl)oxy)ethyl)-2-phenyl-1,3-dioxan-4-yl)pent-4-en-2-ol 
• 100-52-7 benzaldehyde 

Downstream Products

• 1443040-76-3 (S)-1-((2R,4R,6R)-6-(((2R,4R,6R)-6-((R)-2-((tert-butyldimethylsilyl)oxy)heptadecyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)pent-4-en-2-ol 
• 1443040-81-0 (R)-1-((2R,4R,6S)-6-(((2S,4R,6S)-6-(((S)-6-oxo-3,6-dihydro-2H-pyran-2-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)heptadecan-2-yl acetate 
• 1443040-80-9 (S)-1-((2S,4S,6R)-6-(((2R,4S,6R)-6-((R)-2-acetoxyheptadecyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)pent-4-en-2-yl acrylate 
• 1443040-79-6 (S)-1-((2S,4S,6R)-6-(((2S,4S,6S)-6-((R)-2-hydroxyheptadecyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)pent-4-en-2-yl acrylate 
• 1443040-78-5 (S)-6-(((2S,4S,6R)-6-(((2R,4R,6R)-6-((R)-2-((tert-butyldimethylsilyl)oxy)heptadecyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-5,6-dihydro-2H-pyran-2-one 
• 1443040-77-4 (S)-1-((2S,4S,6R)-6-(((2R,4R,6R)-6-((R)-2-((tert-butyldimethylsilyl)oxy)heptadecyl)-2-phenyl-1,3-dioxan-4-yl)methyl)-2-phenyl-1,3-dioxan-4-yl)pent-4-en-2-yl acrylate 

Relevant academic research and scientific papers

Asymmetric Iterative Hydration of Polyene Strategy to Cryptocaryols A and B

The development of two iterative asymmetric hydration approaches to the synthesis of all syn- and syn/anti/syn-1,3,5,7-tetraol motifs is described. These pseudo-symmetric products are synthetic precursors for 1,3-hexol products. The utility of the route to the all syn-1,3,5,7-tetraol diastereoisomer was demonstrated with its use in the synthesis of cryptocaryols A and B, as well as, stereoisomers.

Cryptocaryol Structure-Activity Relationship Study of Cancer Cell Cytotoxicity and Ability to Stabilize PDCD4

The synthetic cryptocaryols A and B and a series of their analogues have been evaluated for their cytotoxicity and their ability to stabilize the tumor suppressor PDCD4. Cytotoxicities in the 3 to 30 μM range were found. Both the cytotoxicity and PDCD4 stabilizing ability were tolerant of large stereochemical changes to the molecule. Co-dosing studies with cryptocaryols A and B and several known cancer drugs showed no measuable enhancement in cancer drug cytotoxicity.